Take a look behind the scenes of a recent Future Virology editorial entitled, ‘An insight into dengue virus proteins as potential drug/vaccine targets’, as we ask author Muhammad Faheem about recent advances in understanding dengue proteins and where the next 5–10 years could take us.
Browsing: Emerging Disease > Dengue
Scientists have synthetically engineered mosquitoes to prevent transmission of dengue virus to humans. This potentially could lead to genetic approaches to controlling the spread of dengue virus among populations.
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
A team of researchers presented the first large-scale evidence that releasing Wolbachia-infected mosquitoes reduced dengue infections by >70% in high-risk populations.
Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.
A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.
Take a look at this month’s industry headlines including an FDA approval for a vaccine protecting against six diseases, positive clinical trial results for bacteraemia and dengue vaccines and new funding for CRSIPR-based antimicrobials.
The US FDA has granted priority review for Sanofi Pasteur’s dengue vaccine, Dengvaxia®, despite its controversial past.
The first citywide deployment of Wolbachia has proved successful, with no dengue cases reported since Wolbachia became established.